192 related articles for article (PubMed ID: 29633515)
1. Intermittent vs continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer - a phase III study (PRINCE).
Cash H; Steiner U; Heidenreich A; Klotz T; Albers P; Melchior S; Martus P; Fuller F; Magheli A; Hinz S; Kempkensteffen C; Miller K;
BJU Int; 2018 Nov; 122(5):774-782. PubMed ID: 29633515
[TBL] [Abstract][Full Text] [Related]
2. Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network.
Bianchi S; Mosca A; Dalla Volta A; Prati V; Ortega C; Buttigliero C; Fea E; Vanella P; Valcamonico F; Zamparini M; Sirotova Z; Chiappino I; Dal Canton O; Masini C; Sacco C; Amoroso D; Montagnani F; Comandone A; Bellissimo AR; Ciccone G; Baier S; Gennari A; Tucci M; Berruti A
Eur J Cancer; 2021 Sep; 155():127-135. PubMed ID: 34371442
[TBL] [Abstract][Full Text] [Related]
3. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
4. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
George DJ; Halabi S; Healy P; Barak I; Winters C; Anand M; Wilder R; Klein M; Martinez E; Nixon AB; Harrison MR; Szmulewitz R; Armstrong AJ
Prostate; 2019 Nov; 79(15):1752-1761. PubMed ID: 31497882
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer.
Yamashita T; Shiota M; Machidori A; Kobayashi S; Matsumoto T; Monji K; Kashiwagi E; Takeuchi A; Takahashi R; Inokuchi J; Shiga KI; Yokomizo A; Eto M
Cancer Invest; 2021 Mar; 39(3):251-256. PubMed ID: 33393849
[TBL] [Abstract][Full Text] [Related]
6. A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial.
Bouman-Wammes EW; van den Berg HP; de Munck L; Beeker A; Smorenburg CH; Vervenne WL; Coenen JLLM; Verheul HMW; Gerritsen WR; Van den Eertwegh AJM
Eur J Cancer; 2018 Feb; 90():1-9. PubMed ID: 29268139
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel.
Buttigliero C; Tucci M; Vignani F; Di Stefano RF; Leone G; Zichi C; Pignataro D; Lacidogna G; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
Clin Genitourin Cancer; 2018 Aug; 16(4):318-324. PubMed ID: 29866495
[TBL] [Abstract][Full Text] [Related]
8. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
9. Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration.
Shigeta K; Kosaka T; Hongo H; Yanai Y; Matsumoto K; Morita S; Mizuno R; Shinojima T; Kikuchi E; Oya M
Int J Clin Oncol; 2019 May; 24(5):546-553. PubMed ID: 30604159
[TBL] [Abstract][Full Text] [Related]
10. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG
Eur Urol; 2019 Sep; 76(3):306-312. PubMed ID: 30466891
[TBL] [Abstract][Full Text] [Related]
11. Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
Ito K; Kimura T; Onuma H; Tabata R; Shimomura T; Miki K; Tomita M; Egawa S
Prostate; 2018 May; 78(7):498-505. PubMed ID: 29473179
[TBL] [Abstract][Full Text] [Related]
12. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
[TBL] [Abstract][Full Text] [Related]
13. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I
Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168
[TBL] [Abstract][Full Text] [Related]
14. Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.
Hamid AA; Willson K; Vincent AD; Tamjid B; Lee M; Bergin A; Gan C; Campbell A; Stewart J; Pezaro C; Tran B; Weickhardt AJ
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e399-e404. PubMed ID: 29318740
[TBL] [Abstract][Full Text] [Related]
15. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
[TBL] [Abstract][Full Text] [Related]
16. Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
Oudard S; Fizazi K; Sengeløv L; Daugaard G; Saad F; Hansen S; Hjälm-Eriksson M; Jassem J; Thiery-Vuillemin A; Caffo O; Castellano D; Mainwaring PN; Bernard J; Shen L; Chadjaa M; Sartor O
J Clin Oncol; 2017 Oct; 35(28):3189-3197. PubMed ID: 28753384
[TBL] [Abstract][Full Text] [Related]
17. An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
Carles J; Pichler A; Korunkova H; Tomova A; Ghosn M; El Karak F; Makdessi J; Koroleva I; Barnes G; Bury D; Özatilgan A; Hitier S; Katolicka J
BJU Int; 2019 Mar; 123(3):456-464. PubMed ID: 30098093
[TBL] [Abstract][Full Text] [Related]
18. Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer.
Passildas-Jahanmohan J; Eymard JC; Pouget M; Kwiatkowski F; Van Praagh I; Savareux L; Atger M; Durando X; Abrial C; Richard D; Ginzac Couvé A; Thivat E; Monange B; Chollet P; Mahammedi H
Cancer Med; 2021 Apr; 10(7):2332-2340. PubMed ID: 33666378
[TBL] [Abstract][Full Text] [Related]
19. A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
Hussain M; Rathkopf D; Liu G; Armstrong A; Kelly WK; Ferrari A; Hainsworth J; Joshi A; Hozak RR; Yang L; Schwartz JD; Higano CS
Eur J Cancer; 2015 Sep; 51(13):1714-24. PubMed ID: 26082390
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Petrylak DP; Vogelzang NJ; Budnik N; Wiechno PJ; Sternberg CN; Doner K; Bellmunt J; Burke JM; de Olza MO; Choudhury A; Gschwend JE; Kopyltsov E; Flechon A; Van As N; Houede N; Barton D; Fandi A; Jungnelius U; Li S; de Wit R; Fizazi K
Lancet Oncol; 2015 Apr; 16(4):417-25. PubMed ID: 25743937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
